Based on a long-standing historic track-record, we have state-of-the-art and readily available vaccine platform technologies and development capabilities. In recent years, we further developed these scale-able platform technologies that can be applied to quickly develop vaccines.
In our state-of-the-art facilities, our experienced R&D institute takes your discovery up to Phase I/II clinical trials. Furthermore, we share and transfer our knowledge and technologies to public and private partners worldwide and work on collaborative R&D.
Our aim is worldwide equity in access to affordable vaccines. Achieving our aim requires a wide range of expertises in the field of vaccinology and intense interdisciplinary collaboration.
Intravacc provides the know-how and tools to support the development of innovative ideas from universities and start-ups into concept products that are interesting for pharmaceutical companies who are able to bring vaccines to the market. These crucial development phases from research up to clinical phase I/II studies ask for highly professional expertise and infrastructure.
Through co-development and by transferring vaccine technologies and knowledge, we partner with vaccine manufacturers worldwide to develop or improve their vaccine production processes and analytical assays, thereby enhancing both the quality and the quantity of global vaccine manufacturing.
Our programs and projects are supported by the Netherlands Government, the European Union, the World Health organization (WHO) and the Bill and Melinda Gates Foundation.
With our Polio Expertise Center, we contribute to the eradication of polio worldwide. We use our proven platform technologies to swiftly develop an affordable, high quality polio vaccine in accordance with EMA and WHO requirements.
Polio is a severe disease and once infected, there is no cure. Prevention is the key word, and fortunately there are effective vaccines against polio. To prevent future outbreaks, vaccination will remain necessary, even after eradication. To increase polio vaccine availability and accessibility, on assignment by the World Health Organization, we developed a new inactivated polio vaccine.
Intravacc serves as an expert center to improve your polio vaccine by:
We use a science-based quality by design (QbD) approach following ICH Q8 and ICH Q11 guidelines for low cost-of-goods virus vaccines based on an available scale-down process for inactivated polio vaccines.
By using the weakened and less transmissible Sabin polioviruses in production, the risk of facility related outbreaks can be reduced significantly. Therefore, our technology allows manufacturers to securely produce Sabin-IPV (Inactivated Polio Vaccine), and in this way also actively contribute to the GPEI goals for polio eradication.
In recent clinical studies the new Sabin-IPV was successfully shown to be safe and immunogenic in both adults and infants.
The implementation of post-eradication containment requirements (GAPIII) may influence the activities in future polio virus vaccine research, and in production facilities. Therefore, alternative poliovirus strains and methods are actively being developed that could reduce the risk of facility-associated transmission and may require lower levels of containment. For example, new Oral Polio Vaccine type 2 (nOPV2) strains are being developed as commissioned by the Bill and Melinda Gates Foundation. Currently, based on our established platform technologies, Intravacc is producing the polio virus nOPV2 Master- and Working seed lots in this project under cGMP.
We have longstanding historic track record in transferring knowledge and technology, for example regarding Hib conjugate vaccine, and influenza vaccine (WHO program). Currently, our Sabin-IPV production technology, including the product specific assays, is actively being transferred by hands-on training to local vaccine manufacturers in emerging economies. For example, in this way China, South Korea and India are enabled to safely produce the Sabin-IPV vaccine to vaccinate their local population and for international supply to UNICEF. We are open for new collaborations, and licensure of our unique Sabin-IPV technology.
In parallel, continued process optimization and modernization is ongoing. This will contribute to increase the affordable Sabin-IPV quantities available for the post-eradication era.
The Sabin-IPV vaccine is developed on our proven Vero cell platform technology. These platform technologies can also be applied to quickly develop several other viral vaccines to control emergency outbreaks.
The use of laboratory animals often remains a necessity in biomedical research. Intravacc acknowledges that laboratory animals are sentient beings and as such, have an intrinsic value. Therefore we have an active research program on Replacing, Reducing and Refining animal use; the so-called 3Rs.
It is our ambition to replace the use of animals for routine lot release testing of (classical) vaccines by innovative animal-free techniques and to improve the scientific substantiation of these methods.
To achieve this, Intravacc is developing several methods based on the 3R’s (reduction, refinement & replacement) of which some have already been adopted by the European Pharmacopoeia. In addition, we are a front runner in the development and distribution of a new paradigm in vaccine lot release testing, known as the consistency approach. To promote the implementation of this strategy, we participate in a IMI-funded European consortium on consistency testing.
We have a profound interest to cooperate within both public and industrial partnerships to improve the 3R research, that currently focusses on:
Intravacc acknowledges that laboratory animals are sentient beings and as such, have an intrinsic value. Therefore, we use use high quality and welfare standards for animal experimentation.
We have a long standing track record in the performance of animal experiments. We are specialized in animal model infectiology and vaccinology. Our Animal Research Center has three state-of-the-art animal laboratory facilities for housing different species of experimental animals, e.g. (transgenic) mice, rats, cotton rats, ferrets, guinea pigs, rabbits etc.
All species can be housed in accommodations with different containment restrictions and biosafety levels. The flexibility of the animal facilities (i.e various closed compartments and 65 stainless steel isolators) offers the possibility to create tailor-made conditions for each animal species under the optimal housing restrictions and biosafety level BSL-2/DM-II and BSL-3/DM-III.
We pay specific attention to guarantee the microbiological status of the animals during the study. With ISO 9002 and ISO 14001, GMP and GLP quality requirements we can ensure that animal experiments are carried out at a very high quality level. All animal experiments are performed in accordance with the Dutch Law of animal experiments (Wod) and the European Directive 2010/63/EU. The ethical permissibility of the experiment is assessed before the start of each study and during the experiments the animal welfare is monitored by experts according the Wod.
To ensure state of the art expertise and knowledge, we offer innovative research and have several development programs on vaccine delivery and formulation.
We are continuously working to optimize vaccine design and monitoring strategies. The pillars to support translational vaccinology comprise of:
KNOWLEDGE - What should a certain vaccine ideally look like and why?
TOOLS & ASSAYS - How to optimize and monitor vaccine development?
The way this is accomplished by Intravacc varies from collaboration with research institutes/universities/companies to a customer service, examples include:
The ideal vaccine is highly efficacious, easy to administer, thermostable and capable of providing life-long immunity against a given pathogen. Unfortunately, not all vaccines are ideal.
We aim to optimize the efficacy of existing and future vaccines. In addition, optimization of the administration of vaccines can lead to thermostable, pain free and affordable vaccination. Using its proven track record, Intravacc focuses amongst others on improved and innovative techniques for subcutaneous, intramuscular, dermal and mucosal vaccination. By combining innovation and knowledge into a product-oriented approach Intravacc contributes to improved vaccine delivery worldwide.
The Intravacc Vaccine Delivery Platform focuses with its partners on
Our experienced team is working on the stabilization of vaccines and diagnostics by delivering an appropriate formulation suitable for storage in either a liquid or a dried presentation. We offer various drying methods such as spray-drying, freeze-drying, vacuum-drying or foam-drying depending on your needs. We will execute the work in an ML-II environment and are experienced in formulating and drying of genetically modified microorganisms.
We have a broad arrange of equipment, amongst which are:
Intravacc strives for an efficient optimization of drying processes with a minimal risk for failure to guarantee product excellence. Therefore, we offer the following services:
Intravacc is an experienced, not-for-profit R&D organization. We optimize vaccines, vaccine processes and vaccine technologies. Our aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide.
We achieve our aim by developing and improving vaccine design, production processes, analytics and technologies. In our state-of-the-art facilities, our experienced R&D institute takes your discovery up to Phase I/II clinical trials. Furthermore, we share and transfer our knowledge and technologies to public and private partners worldwide and work on collaborative R&D.
Our client base:
Our institute in short:
Recently, the PhD thesis of René Raeven appeared entitled ’Systems vaccinology – Molecular signatures of immunity to Bordetella pertussis’. In this thesis, the immune responses following <...
The European Vaccine Initiative (EVI) is leading European efforts to develop effective, accessible and affordable vaccines against diseases of poverty. Intravacc is represented in the board of EVI....
On the 30th of June, the finals of the yearly Design competition, part of the master programme in Life Science & Technology at the TU Delft, took place at Intravacc. Five teams, of five student...
European public and private organisations, including Intravacc, are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2) to develop and validate quality test...
One of Intravacc’s senior scientists, Ahd Hamidi, recently submitted her doctoral thesis on the development and technology transfer of a low-cost, high quality Hib vaccine to local vaccine manufact...
Recently, the PhD thesis of René Raeven appeared entitled ’Systems vaccinology – Molecular signatures of immunity to Bordetella pertussis’. In this thesis, the immune responses following Bordetella pertussis infection and immunization with different pertussis vaccines have been investigated and described in detail. This knowledge is essential for the development of improved pertussis vaccines and optimization of the vaccination strategy.
The research has been performed at the Institute for Translational Vaccinology (Intravacc) in close collaboration with the National Institute for Public Health and Environment (RIVM) and the Leiden Academic Center for Drug Research (LACDR).
Pertussis, a severe respiratory infectious disease that is especially dangerous for babies, is still endemic despite high vaccination coverage. It is therefore present in the top 10 of vaccine-preventable diseases that still circulate. The worldwide resurgence of Bordetella pertussis infections is associated with pathogen adaptation and suboptimal immunity induced by the current vaccines. Therefore, improved vaccines are required.
In this research, an experimental outer membrane vesicle pertussis vaccine, developed at Intravacc, has been compared in detail with current marketed vaccines; the acellular vaccine, containing purified pertussis proteins, and the classic whole-cell vaccine, that contains the complete inactive bacteria. The results indicate that immunization with outer membrane vesicles provides excellent protection in mice against a Bordetella pertussis infection. The immune responses are directed against much more antigens compared to the acellular vaccine. This is of great importance as a broader response may provide protection against different Bordetella pertussis strains. Moreover, the outer membrane vesicles induce less pro-inflammatory cytokines that are associated with reactogenic side effects compared to the classic whole-cell vaccine.
The researchers additionally investigated the immune responses following a Bordetella pertussis infection itself that infects through nose and lungs. Whereas the infection-induced immunity does also not provide life-long protection, the duration of protection is better compared to that induce by current pertussis vaccines. This improved protection is mainly attributed to the induction of specific responses in the lung itself. Such local response at the site of infection are not induced by the vaccines that are injected into the system. Immunization of the outer membrane vesicles directly into the lungs demonstrated that this induces the similar superior responses as induced by Bordetella pertussis infection even though the vesicles are not capable of infecting the lungs. This pinpoints the importance for the route of immunization as a valuable parameter for improving pertussis vaccines.
The application of systems vaccinology demonstrates that a comprehensive insight into the immune responses following immunization can contribute to optimizing the safety, efficacy and application of vaccines. In addition, it enables to compare the responses between vaccines.
The defense of the PhD thesis will take place on September 22, 15.00 at the University of Leiden.
On the 30th of June, the finals of the yearly Design competition, part of the master programme in Life Science & Technology at the TU Delft, took place at Intravacc. Five teams, of five students each, worked independently towards a complete design of a cost-effective MenB (meningococcal B) vaccine. The main objective of this Design competition was to evaluate the actual NonaMen process developed by Intravacc and propose the best option for a MenB vaccine process to be implemented at commercial scale, taking into account the market dynamics and product potential. The competition was organized in cooperation with Intravacc, TU Delft and BE-Basic Foundation. The winning team presented a complete process and business design and had proposed optimizations of the current Intravacc process leading to a lower production cost. They were awarded with a prize of €400. To read the full press release, follow this link.
European public and private organisations, including Intravacc, are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2) to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.
For more information and full press release, follow link.
One of Intravacc’s senior scientists, Ahd Hamidi, recently submitted her doctoral thesis on the development and technology transfer of a low-cost, high quality Hib vaccine to local vaccine manufacturers in emerging countries like China, India and Indonesia. On March 3rd at TU Delft she defended successfully her thesis. In relation to her PhD graduation, the independent student newspaper of TU Delft, ‘Delta’, interviewed Dr. Hamidi about her general motives and methods. If you’re interested in reading the full interview (in Dutch), please follow this link.
Het Instituut voor Translationele Vaccinologie (Intravacc) is dé plek in Nederland met een breed toegankelijke en complete infrastructuur voor translationele vaccinonderzoek en -ontwikkeling. Op het instituut worden goede ideeën uit de wetenschap verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Het instituut rekent zowel de (inter)nationale overheden als diverse farmaceutische en biotech bedrijven tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd tot een publiek-private onderneming.
Binnen Intravacc zijn we op zoek naar een:
Wetenschappelijk Medewerker / (Organisch) Chemicus (m/v) (36 uur per week)
Bij de ontwikkeling van nieuwe vaccins speelt chemie een steeds belangrijker rol. Je draagt bij aan projecten waarin chemische synthese en analyse prominent aanwezig zijn. Het betreft zowel product-ontwikkelprojecten als onderzoeksprojecten:
Het salaris is, afhankelijk van opleiding en ervaring, maximaal EUR bruto € 5.067,04 per maand (BBRA-schaal 12 op basis van een volledig dienstverband, 36-urige werkweek), exclusief 8% vakantietoelage en een eindejaarsuitkering van 8,3%. Je wordt aangesteld als Wetenschappelijk Medewerker volgens de indeling in het Functiegebouw Rijk. De aanstelling is voor één jaar. De voorkeur gaat uit naar een fulltime dienstverband.
Voor meer informatie over de functie kun je terecht bij de heer dr. J.E.R. Thole, Hoofd afdeling Research, telefoon: 030-7920529 of de heer dr. G.F.A. Kersten, Sr. Wetenschappelijk Medewerker, telefoon: 030-7920460.
Je sollicitatie kun je sturen tot 16 december 2016 naar firstname.lastname@example.org
Binnen Intravacc zijn we op zoek naar een:
Onderzoeksmedewerker Down Stream Processing (m/v)
Als onderzoeksmedewerker DSP draag je bij aan de procesontwikkeling van diverse virale vaccins. Je voert werkzaamheden uit op het gebied van de zuivering van vaccincomponenten, waarbij de nadruk ligt op het ontwikkelen, optimaliseren en valideren van filtratie- en chromatografieprocessen.
Het werk wordt uitgevoerd in ingeperkte ruimtes (BSL-2/ML-II). Aandacht voor zowel veiligheidseisen, als kwaliteitseisen (GLP, GMP) zijn belangrijk voor het uitvoeren van de functie.
Je werkt zelfstandig maar je bent ook een goede teamspeler met oog voor interne samenwerkingsverbanden. Je stemt de onderzoeksopzet en laboratoriumwerkzaamheden af binnen het team. Je rapporteert de onderzoeksresultaten mondeling en schriftelijk aan de projectleider. Er wordt van je verwacht dat je een bijdrage kunt leveren aan het schrijven van eindrapportages en publicaties.
Het salaris is, afhankelijk van opleiding en ervaring, maximaal € 3240,81 bruto per maand (BBRA-schaal 8) op basis van een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage en 8,3% eindejaarsuitkering.
Je wordt aangesteld in tijdelijke dienst voor een periode van 12 maanden.
Voor meer informatie over de functie kun je terecht bij Daniëlle Lankveld, afdelingshoofd PD, telefoon 030- 274 2056 of Yvonne Thomassen, senior scientist virale vaccins, telefoon: 030-274 8509.
Je sollicitatie kun je sturen tot 12 december 2016 naar email@example.com